Pembrolizumab (P) in patients (Pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Authors

Ajjai Shivaram Alva MD
Pam K. Mangat MSFollow
Elizabeth Garrett-Mayer PhDFollow
Susan Halabi PhDFollow
Ricardo H. Alvarez MD
Carmen Julia Calfa MDFollow
Maged Khalil MD, Lehigh Valley Health NetworkFollow
Eugene R. Ahn MDFollow
Timothy Lewis Cannon MDFollow
Pamela Crilley DOFollow
Julie Gottlieb Fisher MPH
Derrick S. Haslem MDFollow
Sagun Shrestha MDFollow
Kaitlyn R. AntonelliFollow
Nicole L. Butler MPHFollow
Sasha L. Warren CCRCFollow
Andrew Lawrence Rygiel MPHFollow
Shamika Ranasinghe MSFollow
Suanna S. Bruinooge MPHFollow
Richard L. Schilsky MDFollow

Publication/Presentation Date

5-31-2019

Published In/Presented At

Alva, A., Mangat, P., Garrett-Mayer, E., Halabi, S., Alvarez, R., Calfa, C., Khalil, M., Ahn, E., Cannon, T., Crilley, P., Fisher, J., Haslem, D., Shrestha, S., Antonelli, K., Butler, N., Warren, S., Rygiel, A., Ranasinghe, S., Bruinooge, S., & Schilsky, R. (2019, May). Pembrolizumab (P) in patients (Pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Presentation presented at ASCO 2019 Annual Meeting, Chicago, IL.

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation